GLP‑1s reshape gym culture
Clinics and gyms report a cultural shift as GLP‑1 medications change who shows up in strength areas—trainers note more people are pursuing resistance training to pair with pharmaceutical weight loss. The trend is quietly altering floor traffic and exercise goals, with strength work rising in prominence alongside metabolic therapies (self.com)
Monthly semaglutide prescription fills rose from 471,876 in 2021 to 2,555,308 in 2023, a roughly 442% increase in retail pharmacy activity. (healio.com) National polls show rapid uptake: a KFF Health Tracking Poll found about 12% of U.S. adults report having taken a GLP‑1, and Gallup data reported use rising to 12.4% from 5.8% since early 2024. (kff.org) Bank analysts project continued expansion: J.P. Morgan estimates roughly 25 million Americans could be on GLP‑1 treatment by 2030 and forecasts the global incretin market near $200 billion by 2030. (jpmorgan.com) Regulatory and clinical context: the FDA approved tirzepatide (Zepbound) for chronic weight management on Nov. 8, 2023, based on two 72‑week randomized trials that enrolled 2,519 treated patients and 958 placebo patients. (fda.gov) Market and fitness-sector responses are concrete: an industry tracker in Q1 2026 documented 17 fitness clubs and 10 solution providers with active GLP‑1 integration projects, from clubs prescribing directly to budget chains partnering with telehealth platforms. (cdn.prod.website-files.com) Workforce data: a NASM survey of nearly 500 fitness professionals flagged role changes across the industry and found 60% of clients on GLP‑1s expressing concern about losing critical muscle mass. (insider.fitt.co) Clinical‑sector reports urge action: a Les Mills/ukactive review found 20–50% of weight lost on these medications can be lean mass and called for coordinated strength‑training and protein strategies as part of care, noting ~2.5 million UK users at the time of the report. (lesmills.com)
